News from us and our partners

Tags

Topics

0 results

News
7 March, 2017
Sofinnova Partners invests in AgroSavfe
News
7 March, 2017
Dr Igor Matushansky Appointed Global Head, Research and Development of Hookipa Biotech
News
2 March, 2017
Sofinnova Partners raises €106 million in a first closing of its Industrial Biotech Fund
News
28 February, 2017
Comet Biorefining Completes Equity Financing
News
22 February, 2017
Lysogene Receives Orphan Drug Designation from EMA for LYS-GM101 for Treatment of GM1 Gangliosidosis
News
22 February, 2017
Michael Clayman, M.D., CEO of Flexion Therapeutics talk about the need for new treatment options for osteoarthritis (OA) and Flexion’s lead investigational product candidate, ZilrettaTM
News
21 February, 2017
BioAmber CEO steps down, current COO Fabrice Orecchioni named President
News
14 February, 2017
Pixium Vision receives NUB innovation reimbursement Status-1 for 150 electrode IRIS®II bionic system in Germany
News
7 February, 2017
Lysogene announces its successful IPO on Euronext Paris with nearly €22.6 m raised
News
1 February, 2017
Mainstay Medical Starts Commercialization of ReActiv8® for the Treatment of Chronic Low Back Pain
News
26 January, 2017
Sofinnova Partners announces the acquisition of Delinia by Celgene Corporation
News
25 January, 2017
ObsEva SA Announces Pricing of Initial Public Offering
News
23 January, 2017
DNA Script adds Dr. Heiner Dreismann, former CEO of Roche Molecular Diagnostics, to Board of Directors
News
19 January, 2017
Cerenis - Clinical progress, cash position and revenue for Q4 2016
News
17 January, 2017
ObsEva Expands Leadership Team and Board of Directors with Industry Veterans
News
13 January, 2017
STENTYS- 2016 Annual Revenues up 20% at €7.3 Million

Sofinnova Partners invests in AgroSavfe

Dr Igor Matushansky Appointed Global Head, Research and Development of Hookipa Biotech

Sofinnova Partners raises €106 million in a first closing of its Industrial Biotech Fund

Comet Biorefining Completes Equity Financing

Lysogene Receives Orphan Drug Designation from EMA for LYS-GM101 for Treatment of GM1 Gangliosidosis

Michael Clayman, M.D., CEO of Flexion Therapeutics talk about the need for new treatment options for osteoarthritis (OA) and Flexion’s lead investigational product candidate, ZilrettaTM

BioAmber CEO steps down, current COO Fabrice Orecchioni named President

Pixium Vision receives NUB innovation reimbursement Status-1 for 150 electrode IRIS®II bionic system in Germany

Lysogene announces its successful IPO on Euronext Paris with nearly €22.6 m raised

Mainstay Medical Starts Commercialization of ReActiv8® for the Treatment of Chronic Low Back Pain

Sofinnova Partners announces the acquisition of Delinia by Celgene Corporation

ObsEva SA Announces Pricing of Initial Public Offering

DNA Script adds Dr. Heiner Dreismann, former CEO of Roche Molecular Diagnostics, to Board of Directors

Cerenis - Clinical progress, cash position and revenue for Q4 2016

ObsEva Expands Leadership Team and Board of Directors with Industry Veterans

STENTYS- 2016 Annual Revenues up 20% at €7.3 Million